Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Handelsbanken Fonder AB acquired a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 21,000 shares of the company’s stock, valued at approximately $1,343,000.

A number of other institutional investors also recently modified their holdings of KNSA. EverSource Wealth Advisors LLC raised its stake in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International during the second quarter valued at $31,000. KBC Group NV acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth about $34,000. Smartleaf Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 4th quarter worth about $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. 53.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the sale, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Up 0.4%

Shares of NASDAQ KNSA opened at $79.49 on Wednesday. The firm has a market capitalization of $6.20 billion, a P/E ratio of 81.95 and a beta of 0.05. The firm’s 50-day moving average price is $65.64 and its 200-day moving average price is $54.24. Kiniksa Pharmaceuticals International, plc has a 1-year low of $32.89 and a 1-year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current year.

Analyst Ratings Changes

KNSA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Jefferies Financial Group boosted their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Finally, The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.38.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.